Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and effectiveness after single-dose giroctocogene fitelparvovec or fidanacogene elaparvovec in hemophilia A/B
jRCT2033260314Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies, Gene Therapies
01
Overview
Phase 3, open-label trial of giroctocogene fitelparvovec and fidanacogene elaparvovec in hemophilia A and hemophilia B (HB) (2 cohorts), sponsored by Pfizer. Primary endpoints: Incidence of thromboembolic events, Incidence of factor inhibitor development and 3 more. Started Jan 2020; status: recruiting.
02
Drugs
giroctocogene fitelparvovecfidanacogene elaparvovec
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on jRCT2033260314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033260314.